

Supplementary references

(1-43)

1. Gustafsson, C., Mjosberg, J., Matussek, A., Geffers, R., Matthiesen, L., Berg, G., Sharma, S., Buer, J., and Ernerudh, J. 2008. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. *PLoS One* 3:e2078.
2. Palani, S., Maksimow, M., Miiluniemi, M., Auvinen, K., Jalkanen, S., and Salmi, M. Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. *Eur J Immunol* 41:2052-2063.
3. Klimchenko, O., Di Stefano, A., Georger, B., Hamidi, S., Opolon, P., Robert, T., Routhier, M., El-Benna, J., Delezoide, A.L., Boukour, S., et al. Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. *Blood* 117:3065-3075.
4. Si, Y., Tsou, C.L., Croft, K., and Charo, I.F. CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. *J Clin Invest* 120:1192-1203.
5. Louvet, A., Teixeira-Clerc, F., Chobert, M.N., Deveaux, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A., and Lotersztajn, S. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice. *Hepatology*.
6. Vidal, B., Serrano, A.L., Tjwa, M., Suelves, M., Ardite, E., De Mori, R., Baeza-Raja, B., Martinez de Lagran, M., Lafuste, P., Ruiz-Bonilla, V., et al. 2008. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. *Genes Dev* 22:1747-1752.
7. Murray, L.A., Rosada, R., Moreira, A.P., Joshi, A., Kramer, M.S., Hesson, D.P., Argentieri, R.L., Mathai, S., Gulati, M., Herzog, E.L., et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. *PLoS One* 5:e9683.
8. Cassol, E., Cassetta, L., Rizzi, C., Alfano, M., and Poli, G. 2009. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. *J Immunol* 182:6237-6246.
9. Chan, G., Bivins-Smith, E.R., Smith, M.S., and Yurochko, A.D. 2009. NF-kappaB and phosphatidylinositol 3-kinase activity mediates the HCMV-induced atypical M1/M2 polarization of monocytes. *Virus Res* 144:329-333.
10. Korthagen, N.M., van Moorsel, C.H., Barlo, N.P., Ruven, H.J., Kruit, A., Heron, M., van den Bosch, J.M., and Grutters, J.C. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. *Respir Med* 105:106-113.
11. Salam, M.T., Islam, T., Gauderman, W.J., and Gilliland, F.D. 2009. Roles of arginase variants, atopy, and ozone in childhood asthma. *J Allergy Clin Immunol* 123:596-602, 602 e591-598.
12. Fujisaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsuneyama, K., Nagai, Y., Takatsu, K., Urakaze, M., et al. 2009. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. *Diabetes* 58:2574-2582.
13. Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R., Casali, P.G., et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Cancer Res* 70:2235-2244.
14. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. *Nat Immunol* 3:196-200.
15. Krieg, A.M. 2006. Therapeutic potential of Toll-like receptor 9 activation. *Nat Rev Drug Discov* 5:471-484.

16. Miller, A.M., Asquith, D.L., Hueber, A.J., Anderson, L.A., Holmes, W.M., McKenzie, A.N., Xu, D., Sattar, N., McInnes, I.B., and Liew, F.Y. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. *Circ Res* 107:650-658.
17. Bouhlef, M.A., Chinetti-Gbaguidi, G., and Staels, B. 2007. Glitazones in the treatment of cardiovascular risk factors. *Fundam Clin Pharmacol* 21 Suppl 2:7-13.
18. Hatoum, H.T., Lin, S.J., Guo, A., Lipton, A., and Smith, M.R. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. *Curr Med Res Opin* 27:55-62.
19. Mirolo, M., Fabbri, M., Sironi, M., Vecchi, A., Guglielmotti, A., Mangano, G., Biondi, G., Locati, M., and Mantovani, A. 2008. Impact of the anti-inflammatory agent bindarit on the chemokine: selective inhibition of the monocyte chemotactic proteins. *Eur Cytokine Netw* 19:119-122.
20. Zhao, M., Jiang, B., and Gao, F.H. Small Molecule Inhibitors of STAT3 for Cancer Therapy. *Curr Med Chem*.
21. Bel'skii Iu, P., Bel'skaia, N.V., Danilets, M.G., Trofimova, E.S., Uchasova, E.G., Ligacheva, A.A., and Agafonov, V.I. 2009. [Prospects for pharmacological regulation of macrophage activity by modulation of intracellular signal cascade]. *Vestn Ross Akad Med Nauk*:21-25.
22. Ahmed, A.S., Li, J., Ahmed, M., Hua, L., Yakovleva, T., Ossipov, M.H., Bakalkin, G., and Stark, A. Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132. *Arthritis Rheum* 62:2160-2169.
23. Suzuki, J., Ogawa, M., Muto, S., Itai, A., Isobe, M., Hirata, Y., and Nagai, R. Novel I κ B kinase inhibitors for treatment of nuclear factor- κ B-related diseases. *Expert Opin Investig Drugs* 20:395-405.
24. Ricci, G., Dondi, A., Patrizi, A., and Masi, M. 2009. Systemic therapy of atopic dermatitis in children. *Drugs* 69:297-306.
25. Fonseca, D.E., and Kline, J.N. 2009. Use of CpG oligonucleotides in treatment of asthma and allergic disease. *Adv Drug Deliv Rev* 61:256-262.
26. Gupta, G.K., and Agrawal, D.K. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. *BioDrugs* 24:225-235.
27. Sun, Z., Yao, Z., Liu, S., Tang, H., and Yan, X. 2006. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. *Immunobiology* 211:199-209.
28. Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gibrilovich, D., Heller, R., Coppola, D., et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. *Nat Med* 10:48-54.
29. Sinha, P., Clements, V.K., and Ostrand-Rosenberg, S. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. *J Immunol* 174:636-645.
30. Rodriguez-Sosa, M., David, J.R., Bojalil, R., Satoskar, A.R., and Terrazas, L.I. 2002. Cutting edge: susceptibility to the larval stage of the helminth parasite *Taenia crassiceps* is mediated by Th2 response induced via STAT6 signaling. *J Immunol* 168:3135-3139.
31. Bosschaerts, T., Morias, Y., Stijlemans, B., Herin, M., Porta, C., Sica, A., Mantovani, A., De Baetselier, P., and Beschin, A. IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF- κ B p50 member in *Trypanosoma congolense* infection resistant C57BL/6 mice. *Eur J Immunol*.
32. Smith, K.J., Hamza, S., and Skelton, H. 2004. Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. *Clin Exp Dermatol* 29:505-512.
33. Spaner, D.E., Miller, R.L., Mena, J., Grossman, L., Sorrenti, V., and Shi, Y. 2005. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. *Leuk Lymphoma* 46:935-939.

34. Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., Holen, I., Monkkonen, H., Boccadoro, M., Forni, G., et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. *J Cell Mol Med* 14:2803-2815.
35. Lutgens, E., Lievens, D., Beckers, L., Wijnands, E., Soehnlein, O., Zerneck, A., Seijkens, T., Engel, D., Cleutjens, J., Keller, A.M., et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. *J Exp Med* 207:391-404.
36. Kurowska-Stolarska, M., Stolarski, B., Kewin, P., Murphy, G., Corrigan, C.J., Ying, S., Pitman, N., Mirchandani, A., Rana, B., van Rooijen, N., et al. 2009. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. *J Immunol* 183:6469-6477.
37. Prieur, X., Mok, C.Y., Velagapudi, V.R., Nunez, V., Fuentes, L., Montaner, D., Ishikawa, K., Camacho, A., Barbarroja, N., O'Rahilly, S., et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. *Diabetes* 60:797-809.
38. Schmidt, M.V., Brune, B., and von Knethen, A. The nuclear hormone receptor PPARgamma as a therapeutic target in major diseases. *ScientificWorldJournal* 10:2181-2197.
39. Li, A.C., Brown, K.K., Silvestre, M.J., Willson, T.M., Palinski, W., and Glass, C.K. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. *J Clin Invest* 106:523-531.
40. Abraham, C., and Medzhitov, R. 2011. Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology* 140:1729-1737.
41. Rizzo, A., Monteleone, I., Fina, D., Stolfi, C., Caruso, R., Fantini, M.C., Franze, E., Schwendener, R., Pallone, F., and Monteleone, G. 2011. Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. *Inflamm Bowel Dis*.
42. Anthony, R.M., Urban, J.F., Jr., Alem, F., Hamed, H.A., Roza, C.T., Boucher, J.L., Van Rooijen, N., and Gause, W.C. 2006. Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. *Nat Med* 12:955-960.
43. Zhao, A., Urban, J.F., Jr., Anthony, R.M., Sun, R., Stiltz, J., van Rooijen, N., Wynn, T.A., Gause, W.C., and Shea-Donohue, T. 2008. Th2 cytokine-induced alterations in intestinal smooth muscle function depend on alternatively activated macrophages. *Gastroenterology* 135:217-225 e211.